This 35p UK stock could rise 129%, according to a City broker

This 35p UK stock’s risky. But if analysts at Deutsche Bank are right, it could more than double investors’ money in the years ahead.

| More on:
British flag, Big Ben, Houses of Parliament and British flag composition

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

A lot of small-cap UK stocks have been hammered lately. So there could be some big opportunities in the coming years for those of us who like to take an active approach to investing.

One stock that looks interesting to me right now is Creo Medical (LSE: CREO), which is currently trading for just 35p. According to analysts at Deutsche Bank – who just slapped an 80p price target on it – it has the potential to rise 129% from here.

An innovative healthcare company

Creo Medical’s an innovative medical device company that specialises in instruments for endoscopic (minimally invasive) surgery.

Its flagship product, Speedboat Inject, is a multimodal endoscopic instrument that can be used by surgeons to dissect, cut out, inject, and more when operating on pre-cancer and cancer patients.

Recently, Creo has been having a lot of success with Speedboat Inject. In the first half of 2023, for example, the company saw a 44% increase in its user base from the end of 2022.

However, the group continues to launch new products to diversify its revenue stream. Last year, for instance, it launched Speedboat UltraSlim – a slimmer multi-modal endoscopic device with advanced features.

So far, this product’s been successful in procedures in the UK, USA, Latin America, and Asia to treat pre-cancerous lesions in the colon, oesophagus and stomach.

I can go whatever direction I want with complete rotation and deliver microwave faster. The UltraSlim is a gamechanger.

Feedback from a user of Creo’s Speedboat UltraSlim

Strong growth

Now Creo’s revenues are growing at a healthy rate right now, thanks to its innovative medical devices.

In February, the group announced that revenues for 2023 were likely to be up 13% year on year to £30.8m. This year, City analysts expect revenues to amount to £40.6m. That would equate to growth of 32%.

That’s the kind of numbers I like to see from a smaller company.

Hard to value

The problem from an investment perspective however, is that the company’s quite hard to value because it’s not yet profitable. With no earnings, we can’t get a price-to-earnings (P/E) ratio here.

We can look at the price-to-sales ratio though. Today, the company has a market-cap of about £126m. If it was to achieve the £40.6m sales figure I mentioned above, the price-to-sales ratio would only be 3.1. That’s quite reasonable to my mind, given the growth the company’s expected to generate.

Whether the stock can get to 80p in the medium term though is hard to know. This is likely to depend on revenue forecasts for 2025 and 2026, the outlook for profitability, and sentiment towards small-cap UK shares.

High risk, high reward

It’s worth pointing out that Creo Medical’s a higher-risk stock. There’s no guarantee its products will be successful in the long run. And without profits, the company’s share price is likely to be volatile.

Given the lack of profits, the stock’s a bit too risky for me right now. However, for those with a high tolerance for risk, the stock could be worth considering as a high-risk, high-reward play.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Edward Sheldon has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Small-Cap Shares

Investing Articles

Up 79% in a month, is Angle a penny stock worth considering?

Angle (LON:AGL) is a penny stock that exploded higher over the past few weeks. What has sent this share rocketing?

Read more »

Illustration of flames over a black background
Small-Cap Shares

This 13p penny stock’s on fire! Should I buy it?

This UK penny stock has been making investors a lot of money in recent months. Is it worth buying today…

Read more »

Young black woman walking in Central London for shopping
Investing Articles

This ex-penny stock has an 8.3% yield and recovery potential!

This former penny stock has fallen 34% in a year, but a juicy dividend yield and the potential for a…

Read more »

British Pennies on a Pound Note
Investing Articles

1 ex-penny stock I’m loading up on while it is 34p

Our writer explains why he's recently been investing more money into this former penny stock inside his Stocks and Shares…

Read more »

Light bulb with growing tree.
Investing Articles

Is there still time to snap up this ex-penny stock in May?

A penny stock no more but a promising low-cap company nonetheless. Our writer examines the growth prospects of this sustainable…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

1 penny stock I’d consider buying now while its share price is near 12p

This penny stock’s business looks set to explode into earnings after being a loss-maker for years. I think it’s an…

Read more »

Burst your bubble thumbtack and balloon background
Investing Articles

Below 1.4p, is this penny stock one helluva bargain?

Our writer considers whether the discovery of helium in Tanzania will transform the fortunes of this popular penny stock and…

Read more »

Stack of British pound coins falling on list of share prices
Investing Articles

2 penny stocks this Fool thinks could deliver phenomenal returns!

Penny stocks are a risky but exciting asset class to invest in, prone to wild volatility. Our writer thinks he's…

Read more »